Article citationsMore>>

Clay, A.T. and Sharom, F.J. (2014) Multidrug Resistance Protein: P-Glycoprotein. In: You, G.F. and Morris, M.E., Eds., Drug Transporters: Molecular Characterization and Role in Drug Disposition, 2nd Edition, John Wiley & Sons, Inc., 141-160.
https://doi.org/10.1002/9781118705308.ch9

has been cited by the following article:

• TITLE: Role of P-Gp in Treatment of Cancer

  AUTHORS: Venkata Sai Nithin Reddy Yendapalli, Kelley Williams, Terry Oroszi

  KEYWORDS: P-Glycoprotein (P-Gp), Multi-Drug Resistance (MDR), Cancer Treatment, ABC Transporters, Chemotherapy Resistance, P-Gp Inhibitors, Drug Efflux Mechanisms Fourth-Generation Inhibitors

  JOURNAL NAME: Journal of Cancer Therapy, Vol.16 No.1, January 3, 2025

  ABSTRACT: P-glycoprotein (P-gp), a member of the ATP-binding cassette (ABC) family of transporters, plays a crucial role in the development of multi-drug resistance (MDR) in cancer treatment. P-gp actively pumps chemotherapeutic drugs out of cancer cells, reducing their intracellular concentrations and thereby diminishing their efficacy. This review explores the mechanisms by which P-gp contributes to MDR, including intrinsic and acquired resistance. It also discusses various strategies to inhibit P-gp, such as blocking drug binding sites, interfering with ATP hydrolysis, and altering cell membrane integrity. The potential of fourth-generation P-gp inhibitors and other novel approaches to enhance the effectiveness of cancer therapies is also examined. Understanding and overcoming P-gp-mediated MDR is essential for improving therapeutic outcomes in cancer patients.